Spots Global Cancer Trial Database for Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
Official Title: A Phase I Study of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
Study ID: NCT01968915
Conditions
Study Description
Brief Summary: This study will evaluate safety and tolerability to estimate the maximum tolerated dose and/or recommended dose of oral LCL161 in Japanese patients with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Nagoya-city, Aichi, Japan
Novartis Investigative Site, Kobe-city, Hyogo, Japan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
